Zenas BioPharma, Inc. (ZBIO)
- Previous Close
8.72 - Open
8.60 - Bid 9.14 x 100
- Ask 9.40 x 100
- Day's Range
8.60 - 9.93 - 52 Week Range
5.83 - 26.25 - Volume
129,388 - Avg. Volume
183,067 - Market Cap (intraday)
388.64M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-11.89 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.14
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
zenasbio.comRecent News: ZBIO
View More
Performance Overview: ZBIO
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZBIO
View MoreValuation Measures
Market Cap
388.64M
Enterprise Value
38.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
24.52
Price/Book (mrq)
1.24
Enterprise Value/Revenue
7.78
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.76%
Return on Equity (ttm)
-93.22%
Revenue (ttm)
5M
Net Income Avi to Common (ttm)
-156.99M
Diluted EPS (ttm)
-11.89
Balance Sheet and Cash Flow
Total Cash (mrq)
350.77M
Total Debt/Equity (mrq)
0.32%
Levered Free Cash Flow (ttm)
-60.01M
Research Analysis: ZBIO
View MoreResearch Reports: ZBIO
View MoreDaily – Vickers Top Buyers & Sellers for 02/20/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/05/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/21/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.